Menu Search
Equities

Viromed Medical AG

VMED:DEU

Viromed Medical AG

Actions
  • Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
--
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Viromed Medical AG is a Germany-based company engaged in the supply of medicines. The Company supplies pharma products to clinics, rehabilitation hospitals, nursing homes, medical practitioners, and others. It conducts research on viruses and bacteria along with developing solutions for medical technology such as cold plasma technology used for wound healing, plasma therapy, and produces medical equipment such as ViroCAP, PulmoPlas, used for curative activities such as in the areas of infection protection, dermatology, and intensive care medicine. Its other products and services include nasal sprays, air purifiers, VitaQuiz, corona tests and others.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-80.36k
  • Incorporated2021
  • Employees--
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		VMEDX:GER since
announced		Transaction
value
Activcell Group AGDeal completed17 Sep 202417 Sep 2024Deal completed6.67%--
Data delayed at least 15 minutes, as of Nov 15 2024 16:36 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.